Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

ARNA 3.99 -0.05 (-1.24%)
price chart
Arena Pharmaceutical's Belviq Requires Patience And Understanding (ARNA)
As someone with a relatively oversized long position in Arena Pharmaceuticals (NASDAQ:ARNA) I have been somewhat disappointed in the performance of both the stock and Arena's flagship offering, Belviq. Since the launch of Belviq in the late Spring of ...
Related articles »  
Arena Pharmaceuticals (ARNA) Granted US Patent For Ralinepag
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced yesterday that it been granted composition of matter patent by the US Patent and Trademark Office for its pipeline drug ralinepag for the treatment of vasospastic diseases, including pulmonary ...
Stocks Highlights - Arena Pharmaceuticals, Inc (NASDAQ:ARNA), New York ...  Techsonian (press release)
Related articles »  
Arena's Belviq - Regulatory Update And A Recall (ARNA)
Arena Pharmaceuticals (NASDAQ:ARNA) filed an 8K with the SEC on Friday, offering news of regulatory updates and informing investors of a recall on the anti-obesity drug Belviq.
Related articles »  
Arena: Belviq Sales See Pleasant Rebound
In my opinion, the impacts of the Belviq recall, announced by Arena Pharmaceuticals (NASDAQ:ARNA) last Friday, carried a small impact on the script numbers this week.
Related articles »  
Belviq Sales About What Was Expected For Thanksgiving Week (ARNA)
Belviq, the anti-obesity medication from Arena Pharmaceuticals (NASDAQ:ARNA), saw its week over week scripts drop with this week's numbers.
Related articles »  
Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare ...
SAN DIEGO, Nov. 24, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, +3.59% announced today that the company is scheduled to present a corporate overview and update at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, ...
Related articles »  
Momentum Stocks in Focus: Arena Pharmaceuticals, Inc.(ARNA), Ascena Retail ...
Arena Pharmaceuticals, Inc.(NASDAQ:ARNA)increased 3.69% and closed at $4.04 in the last trading session with the overall traded volume of 2.24 million shares, versus the average volume of 3.23 million shares.
Arena Pharmaceuticals Inc.: Arena Pharmaceuticals Issued Composition of ...
SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the US Patent and Trademark Office granted Arena U.S.
Arena Pharma granted patent for pulmonary hypertension drug  San Diego Source (subscription)
Related articles »  
Orexigen Therapeutics Breaks the Glass Ceiling (ARNA, VVUS, OREX)
The drug was approved in September, and was widely expected to go head-to-head with similar drugs from Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and VIVUS, Inc. (NASDAQ:VVUS). The problem for fans and followers (and shareholders) of OREX was ...
Related articles »  
Healthcare Sector Movers: Idera Pharmaceuticals, Inc. (IDRA), Arena ...
Idera Pharmaceuticals, Inc. (IDRA) has moved with a change from open of 6.31% at mid-day today with a volume of 1,444,781 shares.
Related articles »